At a glance
- Originator Roche
- Class Neuroprotectants; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 26 Jun 2001 No-Development-Reported for Neurological disorders (Prevention) in Switzerland (Unknown route)
- 16 Jul 1998 Preclinical development for Neurological disorders (Prevention) in Switzerland (Unknown route)